

# NEWSLETTER

**Volume 6, June 2023**

**UPDATES IN BRIEF FROM JANUARY – JUNE 2023.**

## NEW INSTITUTIONAL PARTNER



## MEMBERSHIP UPDATE



## ANNOUNCEMENT

- HCC's Patient Advocacy Group has been formed and the team has launched an online support group for patients, survivors and caregivers.
- Monthly meetings are being organised where experts are invited to share information on relevant topics.

## TWO PATIENT SUPPORT GROUP MEETING HAVE BEEN CONDUCTED SO FAR

Topic : Nutrition for Patients and Survivors (Fuel your body & mind to fight cancer)



Mini Menon  
Moderator



Dr. Punit Jain  
Hematologist



Dr. Gayatri Bhat  
Survivor



Rupal Shah  
Dietitian

Topic : Steps towards preventing Infection during treatment



Dr. Abi Manesh  
Department of Infectious Diseases, CMC Vellore



Keertibala Shukla  
Survivor

We are deeply grateful to all our experts

## EDUCATION & TRAINING






### NURSING WEBINARS

HCC nurses group has been organizing monthly webinar on last Tuesday of the month since January 2021, twenty one webinars have been conducted so far. The recordings of these webinars are available on the website:

<http://hemecancer.org/nursing-webinar.php>

Thank you, team!

Nursing Webinars conducted since January-23:

<p>Topic: Role of Nurses in Apheresis Speaker: Mrs. Josephine Suganya Apheresis Nurse Department of Hematology CMC, Vellore</p>	
<p>Topic: Care of Neutropenic Patients Speaker: Ms. Aswathy Asokan, MSc.Nursing (PhD) Pan India Nurse Educator BMT-Hematology department HCG Group of Hospitals</p>	
<p>Topic: Oncologic Emergencies : Recognition and Initial Management Speaker: Ms. Ratnaprabha Pilane Senior Nurse Department of Infection Control Tata Memorial Hospital, Mumbai</p>	
<p>Topic :Basics of Nutrition in Pediatric Oncology for Nurses</p> <p>Speakers: Ms. Nikita Gaonkar CTC, Mumbai Pediatric Onco Nutritionist Cuddles Foundation</p> <p>Ms. Momi Barman BBCI , Guwahati Pediatric Onco Nutritionist Cuddles Foundation</p>	 

### DEO TRAINING

We conducted a data entry operators training program based on the common findings from the source data verification.

DEO workshop training program recordings are now available on the HCC website:

<https://hemecancer.org/training-module.php>

# ONGOING AND UPCOMING RESEARCH

## ONGOING RESEARCH

### Study Title: Induction Related Mortality Score in Acute Myeloid Leukemia: Prospective Validation Study (HCC pRISM-S)

- CTRI Registration No: CTRI/2020/07/026450
- Duration of study: 5 years
- Date of Study commencement: 1st July 2020
- Update: Enrolment is complete, 3 years follow up data collection is going on; Source data verification and data validation is in progress; Initial data was presented as an abstract in ASH 2022

### Study Title: Evaluation of the safety and efficacy of generic low-dose Dasatinib for frontline therapy in chronic-phase chronic myeloid leukemia - A multi-center phase II single-arm study (GLaD Study)

- CTRI Registration No: CTRI/2020/10/028317
- Duration of Study: 2 years
- Date of Study commencement: October 2020
- Update: Study is complete, Manuscript writing is in progress; Initial data was presented as an abstract in ASH 2022

### Study Title: COVID-19 Hematological Cancers Registry of India (CHCRI Study)

- Study Design: Observational [Patient Registry]
- Observational Model: Case-Only
- Time Perspective: Prospective and Retrospect
- Actual Study Start Date: 1st November 2020
- Update: Enrolment is complete, 5-year follow-up data collection is going on; Data validation is in progress; Analysis will be done after completion of long term follow up; Initial data has been published in Blood Cancer Journal

### Study Title: Outcomes and prognostic factors in patients with Burkitt's Lymphoma: Real World Data (BL Study)

- Study design: Observational, retrospective cohort
- Time Perspective: All consecutive patients registered between January 2012 to December 2019
- Update: Study is complete, Manuscript writing is in progress; Initial data was presented as an abstract in ASH 2022

**Cont..**

## **Ongoing research**

Study Title: Epidemiology and treatment outcomes of patients older than 55 years of age with Acute Myeloid Leukemia in India. (HCC Elderly AML)

- Study design: Observational, retrospective cohort
- Time Perspective: All consecutive patients registered between January 2018 to April 2021, based on current WHO criteria
- Update: Data collection is complete, Initial data got selected and was presented as an abstract in ASH 2022 poster presentation, Source data verification is complete, Final data analysis is in progress, Next step would be manuscript writing and publication

Study Title: Care of patients with Acute Myeloid Leukemia during COVID in India - HCC Leucoin Study

- Study Design: Observational, retrospective comparative analysis of data between two time periods
- Time Perspective: A] 1st January 2018 to 31st March 2020 (pre-COVID-19)  
B] 1st April 2020 to 31st August 2021 (COVID-19 era)
- Update: Data collection is complete, Initial data got selected and was presented as an abstract in ASH 2022 poster presentation, Source data verification is complete, Final data analysis is in progress, Next step would be manuscript writing and publication

Study Title: Outcomes of patients with newly diagnosed Acute Myeloid Leukemia - a real world data (AZA/VEN AML Study)

- Study design: Observational, multicenter, retrospective cohort
- Time Perspective: All consecutive patients registered between January 2017 to December 2022
- Update: Data collection is in progress

Study Title: Outcomes of Philadelphia chromosome positive Acute Lymphoblastic Leukemia (Ph+ALL): Analysis from the database of the Hematology Cancer Consortium (Ph+ALL Study)

- Study design: Observational, multicenter, retrospective cohort
- Time Perspective: All consecutive patients registered between Jan 2015 and December 2021 with Ph+ ALL as defined by the demonstration of t(9,22) in the baseline conventional karyotype or FISH or the demonstration of BCR-ABL transcript at the time of diagnosis
- Update: Data collection is in progress

**Cont..**

## **Ongoing Research**

**Study Title: Patterns of care and outcome in AYA lymphomas- A multicenter registry study from India**

- Study design: Observational, multicenter, prospective registry study
- Time Perspective: All consecutive adolescent and young adult cases (15 to 30 years of age) of lymphoma patients registered between January 2017 to December 2022 who had received at least one cycle of chemotherapy
- Update: Data collection is in progress

**Study Title: Outcomes and prognostic factors in patients with Primary Mediastinal B Cell Lymphoma: real world data (PMBCL Study)**

- Study design: Observational, retrospective cohort
- Time Perspective: All the consecutive patients registered between 2015-2020 with diagnosis of Primary Mediastinal B Cell Lymphoma
- Update: Data collection is in progress

**Study Title: Mixed phenotypic acute leukemia -Clinical presentation and outcomes of patients treated with ALL like protocols a multi-institutional study from India (MPAL Study)**

- Study design: Observational, multicenter, prospective cohort study
- Time Perspective: All consecutive diagnosed with mixed phenotypic acute leukemia (MPAL) between January 2018 and 31st March 2022
- Update: Data collection is in progress

**Study Title: To study outcomes in young CML treated with TKI in India (HCC CML-STOUT)**

- Study design: Observational, retrospective cohort
- Time Perspective: Adolescents and young adults (aged 15-29 years) diagnosed with CML in India between January 2015 and 31st March 2022
- Update: Data collection is in progress

**Study Title: Impact of consolidation radiotherapy in bulky Diffuse Large B Cell Lymphoma by PET based response assessment (DLBCL Study)**

- Study design: Observational, multicenter, retrospective cohort
- Time Perspective: All consecutive patients registered between January 2015 to December 2021, Bulky DLBCL treated with curative intent
- Update: Data collection is in progress

## Upcoming Clinical Trials

Study Title: Phase III open labeled randomized controlled study to evaluate the optimal dose of all-trans retinoic acid in the treatment of low and intermediate risk acute promyelocytic leukemia. (HCC-APL22 DOSA Study)

- Study design: Phase III open labeled Randomized Control Trial
- Sample size: 280 patients (140 patients in each arm)
- Study duration: 3 years
- Objective: To evaluate the net treatment benefit (event-free survival, documented infections, differentiation syndrome, hepatotoxicity and neuropathy in decreasing order) between the two study arms.
- Indication: Patient newly diagnosed with Acute Promyelocytic Leukemia and age more than 15 years at diagnosis.
- Update: IEC Submission and MoU signing with centers is in progress.

Study Title: A phase III randomized study to compare a risk-stratified and response-adapted strategy to ABVD regimen in adolescents and adults with advanced-stage Hodgkin lymphoma. (ABVD Hodgkin's Study)

- Study design: Open-label, Phase III randomized study, comparison of two standard-of-care approaches
- Sample size: 200 patients
- Study duration: 4 years accrual, 3 years follow-up since the last patient is enrolled and 10 years for the long-term follow-up phase since the last patient is enrolled.
- CTRI Registration No: CTRI/2020/12/030132
- Objective: To study the difference in three-year FFP between the ABVD regimen and a risk-stratified response-adapted approach in advanced-stage Hodgkin's lymphoma
- Indication: Advanced stage Hodgkin's lymphoma- Lugano stage III and IV disease will be considered, also stage IIA/B with any one of the adverse features like bulky mediastinum, bulky node more than 10cm in diameter, extranodal disease with age  $\geq$  15 years to 60 years
- Update: MoU signing with centers is in progress.

HCC is deeply grateful to its individual & corporate supporters for their generosity.

**INDIVIDUALS AND INSTITUTIONS WITH AN INTEREST IN HEMATOLOGICAL MALIGNANCIES CAN BECOME MEMBERS, REGISTER : [HTTP://HEMECANCER.ORG/MEMBERSHIP.PHP](http://hemecancer.org/membership.php)**